(Q39510746)

12 September 2017

title

Efficacy of abciximab induced platelet blockade using a rapid point of care assay (English)

1 reference

12 September 2017

1

D J Kereiakes

1 reference

12 September 2017

Charles W. Abbottsmith

9

object named as

C W Abbottsmith

1 reference

12 September 2017

M Mueller

2

1 reference

12 September 2017

W Howard

3

1 reference

12 September 2017

P Lacock

4

1 reference

12 September 2017

L C Anderson

5

1 reference

12 September 2017

T M Broderick

6

1 reference

12 September 2017

E M Roth

7

1 reference

12 September 2017

D D Whang

8

1 reference

12 September 2017

publication date

1 June 1999

1 reference

Journal of Thrombosis and Thrombolysis

12 September 2017

published in

1 reference

12 September 2017

volume

7

1 reference

12 September 2017

issue

3

1 reference

12 September 2017

page(s)

265-276

1 reference

Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris

12 September 2017

cites work

1 reference

12 December 2020

Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction

1 reference

12 December 2020

Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade

1 reference

12 December 2020

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

12 December 2020

Rapid platelet-function assay: an automated and quantitative cartridge-based method

1 reference

12 December 2020

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

12 December 2020

Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy

1 reference

12 December 2020

Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group

1 reference

12 December 2020

First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions

1 reference

12 December 2020

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

12 December 2020

Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment

1 reference

12 December 2020

Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial

1 reference

12 December 2020

Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.

1 reference

12 December 2020

Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators

1 reference

12 December 2020

Monitoring platelet GP IIb/IIIa antagonist therapy

1 reference

12 December 2020

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

12 December 2020

Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1008931126871

1 reference

Dimensions Publication ID

12 September 2017

1007150320

0 references

1 reference